BR0213736A - ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace - Google Patents

ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace

Info

Publication number
BR0213736A
BR0213736A BR0213736-4A BR0213736A BR0213736A BR 0213736 A BR0213736 A BR 0213736A BR 0213736 A BR0213736 A BR 0213736A BR 0213736 A BR0213736 A BR 0213736A
Authority
BR
Brazil
Prior art keywords
allenic
hydroxamic acids
disease
tace inhibitors
matrix metalloproteinase
Prior art date
Application number
BR0213736-4A
Other languages
English (en)
Inventor
Vincent Premaratna Sandanayaka
Efren Guillermo Delos Santos
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0213736A publication Critical patent/BR0213736A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C07C29/38—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78—Halides of sulfonic acids
    • C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/87—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"áCIDOS HIDROXâMICOS DE SULFONAMIDA DE ARILA ALêNICA COMO METALOPROTEINASE MATRIZ E INIBIDORES DE TACE". A presente invenção refere-se a compostos de fórmula (I) que são úteis no tratamento das condições de doença mediadas por TNF-<244>, tais como artrite reumatóide, osteoartrite, sepse, AIDS, colite ulcerativa, esclerose múltipla, doença de Crohn, perda da cartilagem degenerativa, rejeição ao enxerto, caquexia, inflamação, febre, resistência à insulina, choque séptico, insuficiência cardíaca congestiva, doença inflamatória do sistema nervoso central, doença inflamatória dos intestinos e HIV.
BR0213736-4A 2001-11-01 2002-10-31 ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace BR0213736A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33605001P 2001-11-01 2001-11-01
PCT/US2002/034904 WO2003037852A1 (en) 2001-11-01 2002-10-31 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors

Publications (1)

Publication Number Publication Date
BR0213736A true BR0213736A (pt) 2004-10-19

Family

ID=23314347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213736-4A BR0213736A (pt) 2001-11-01 2002-10-31 ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace

Country Status (8)

Country Link
US (1) US7282496B2 (pt)
EP (1) EP1440057A1 (pt)
JP (1) JP2005507937A (pt)
CN (1) CN1610661A (pt)
BR (1) BR0213736A (pt)
CA (1) CA2464727A1 (pt)
MX (1) MXPA04004010A (pt)
WO (1) WO2003037852A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436676A1 (en) 2002-06-12 2012-04-04 Symphony Evolution, Inc. Human adam-10 inhibitors
GT200500139A (es) 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
FR2947270B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153653A (en) * 1989-12-25 1992-10-06 Konica Corporation Image forming apparatus
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2193691A1 (en) 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
US5817822A (en) 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
PT757984E (pt) 1995-08-08 2003-02-28 Ono Pharmaceutical Co Derivados de acido hidroxamico uteis para inibir a gelatinase
US6207672B1 (en) 1995-11-13 2001-03-27 Aventis Pharma Deutschland Gmbh Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids
DE19542189A1 (de) 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
ES2233275T3 (es) 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
BR9707010B1 (pt) 1996-01-23 2009-05-05 compostos, composição farmacêutica e composições para inibir metaloproteinase e colagenase do tipo iv.
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1997045402A1 (fr) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Derives de phenylsulfonamide
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
ATE226573T1 (de) 1996-08-28 2002-11-15 Procter & Gamble Heterozyklische metalloproteaseinhibitoren
BR9713182A (pt) 1996-08-28 1999-11-03 Procter & Gamble Amidas de ácido fosfìnico como inibidores de metalo protease de matriz
KR100339296B1 (ko) 1996-08-28 2002-06-03 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 억제제
DE69716934T2 (de) 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
ATE226193T1 (de) 1996-08-28 2002-11-15 Procter & Gamble Substituierte zyklische amine als metalloproteaseinhibitoren
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU743901B2 (en) 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
HUP0000641A3 (en) 1996-10-16 2001-02-28 American Cyanamid Company Madi Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
JP2001503037A (ja) 1996-10-16 2001-03-06 アメリカン・サイアナミド・カンパニー マトリクス金属プロテナイーゼおよびｔａｃｅに対する阻害薬としてのオルト―スルホンアミドヘテロアリールヒドロキサム酸の製造および使用
AU736134B2 (en) 1996-10-16 2001-07-26 Wyeth Holdings Corporation Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO1998017645A1 (en) 1996-10-22 1998-04-30 Pharmacia & Upjohn Company α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
WO1998027069A1 (en) 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
US5859061A (en) 1997-01-17 1999-01-12 Pharmacia & Upjohn Company Bis-sulfonamides hydroxamic acids as MMP inhibitors
NZ336840A (en) 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
EP0960098A1 (en) 1997-02-11 1999-12-01 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
WO1998039313A1 (en) 1998-03-04 1998-09-11 Monsanto Company Thioaryl sulfonamide hydroxamic acid compounds
ATE287885T1 (de) 1997-03-04 2005-02-15 Pharmacia Corp Hydroxamsäure-sulfonamid-derivate mit amidiertem aromatischen ring
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
WO1998043963A1 (en) 1997-04-01 1998-10-08 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022423A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors

Also Published As

Publication number Publication date
JP2005507937A (ja) 2005-03-24
US20030130238A1 (en) 2003-07-10
EP1440057A1 (en) 2004-07-28
MXPA04004010A (es) 2004-07-23
WO2003037852A1 (en) 2003-05-08
CA2464727A1 (en) 2003-05-08
CN1610661A (zh) 2005-04-27
US7282496B2 (en) 2007-10-16

Similar Documents

Publication Publication Date Title
TR200102132T2 (tr) Asetilenik alfa-amino asit temelli sülfonamid hidroksamik asit tace inhibitörleri.
BR9811573A (pt) Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
DK0646595T3 (da) Nukleinsyrer-bindende oligomerer med N-forgrening til terapi og diagnostik
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
DE69426956D1 (de) Nachweis von Mycobakterien durch Nukleinsäure-Multiplexamplifizierung
ATE506450T1 (de) Synthese von oligosacchariden, glykolipiden und glykoproteinen unter verwendung bakterieller glykosyltransferasen
NO965521D0 (no) N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
EA200100809A1 (ru) 2,3,4,5-тетрагидро-1h-[1,4]бензодиазепин-3-гидроксамовые кислоты как ингибиторы матриксных металлопротеиназ
BR0317589A (pt) Método para a remoção de pelìcula biológica
EA200100807A1 (ru) Производные алкинилсодержащих гидроксамовых кислот и их применение в качестве ингибиторов tace
BR0213736A (pt) ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
ATE532877T1 (de) Nukleinsäuremoleküle zum nachweis von bakterien und phylogenetischen einheiten von bakterien
DE59913211D1 (de) Affinitätssensor für den nachweis spezifischer molekularer bindungsereignisse und dessen verwendung
EA200000849A1 (ru) N-гидрокси-2-(алкил-, арил- или гетероарилсульфанил-, сульфинил- или сульфонил)-3-замещенный алкил-, арил- или гетероариламиды в качестве ингибиторов матричных металлопротеиназ
TR200100190T2 (tr) Yeni VLA4 inhibitörü: oMePUPA-V.
DE60015079D1 (de) Acetylenische sulfonamid-thiol-tace-inhibitoren
ATE354622T1 (de) Flüssigkristallines medium
BR0315146A (pt) Composição anti-incrustante, e, método para prevenir incrustração em um processo de ácido (met) acrìlico
BR9915004A (pt) Benzoilpiridazinas
DE602004010587D1 (de) Gewindeabstandhalter
NO20071399L (no) VLA-4-antagonister
WO2003089670A3 (en) Reagents for monitoring nuclei acid amplification and methods of using same
WO2000044710A3 (en) Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
DK0833626T3 (da) Mono- og disulfosubstituerede anthraquioner og deres anvendelse til behandlingen af knoglematrixforstyrrelser

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]